Form4insider filings, from the source

SEC Form 4 · accession 0001445064-15-000099

Keenova Therapeutics plc

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Matthew K Harbaugh
Officer — Sr. VP & CFO
Period of report
Jun 1, 2015
Accepted (ET)
Jun 2, 2015 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Ordinary SharesJun 1, 2015M3,166$34.50A34,539D
Ordinary SharesJun 1, 2015M14,951$31.12A49,490D
Ordinary SharesF1Jun 1, 2015M19,500$33.67A69,099D
Ordinary SharesJun 1, 2015S18,983$128.50D50,116D
Ordinary SharesF2Jun 2, 2015S2,123$129.29D47,993D
Ordinary SharesF3Jun 2, 2015S1,000$130.02D46,993D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Share Options (Right to Buy)$34.50Jun 1, 2015M3,166DDec 1, 2013Nov 30, 2019Ordinary Shares3,1660D
Share Options (Right to Buy)$31.12Jun 1, 2015M14,951DJun 28, 2013Nov 30, 2020Ordinary Shares14,9510D
Share Options (Right to Buy)$33.67Jun 1, 2015M19,500DJun 28, 2013Nov 30, 2021Ordinary Shares19,50022,662D

Explanation of responses